Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis ...Middle East

SAN FRANCISCO and SUZHOU, China , July 3, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic,...

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis )

Also on site :

• Surging travel in Europe spikes concerns over tourism's drawbacks
• Iran& 039;s key nuclear sites & 039;obliterated& 039; by US airstrikes, Trump says
• PRT vs PCC Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ECS T10 Czechia Premier 2025, Qualifier 1